TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04187469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, Isoniazid, Rifampicin
Description: Moxifloxacin 400 mg/day, Rifampicin ≤50 kg 450 mg/day \> 50 kg 600 mg/day, Isoniazid 300 mg/day.~All treatment is taken daily, for a duration of up to 6 months depending on treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin,Isoniazid,Pyrazinamide,Ethambutol
Description: Rifampicin ≤50 kg 450 mg/day, \>50 kg 600 mg/day, Isoniazid 300 mg/day, Pyrazinamide 1500mg/day, Ethambutol ≤50 kg or the elderly 750mg/day, \>50 kg 1000mg/day.~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.
Study: NCT04471792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Creatine monohydrate will be used in combination with muscle stretching.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Cellulose will be used in combination with muscle stretching.
Study: NCT02628418

Intervention type: OTHER
Group type: OTHER
Intervention: General Rehabilitation
Description: All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Rehabilitation
Description: All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Specific hand rehabilitation by Gloreha device
Description: Each training session consisted of six parts:~1. A sequence of digital joint flexion/extension exercises, from the thumb to the fifth finger (7 min);~2. 7 min of a number sequence (counting from one to five);~3. A sequence of thumb-finger opposition movements from the 2nd to the 5th finger (7 min)~4. A sequence of wave-like finger movements (7 min)~5. A sequence of fist opening/closing (7 min)~6. A sequence of flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min).

Intervention type: OTHER
Group type: OTHER
Intervention: Specific hand rehabilitation performed by physiotherapist
Description: The activities were:~1. Flexion-extension of the fingers (10 min);~2. Thumb opposition with the other fingers keeping the forearm in supine position (10 min);~3. Adduction and abduction of the fingers (10 min);~4. Global movement of the hand consisting in reaching for a 0.5l bottle of water, taking hold of it, pouring water into a glass, and then putting the bottle down and letting go of it (10 min).
Study: NCT04542902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dermatophagoides pteronyssinus allergen
Description: Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: An amount of a person's blood taken from their body for use in medical.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: An amount of a person's blood taken from their body for use in medical.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: An amount of a person's blood taken from their body for use in medical.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial challenge with allergen
Description: Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
Study: NCT02417207

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Entecavir combined long-term low-dose HBIG group intramuscular
Description: HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 \~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir combined HBIG group short-term high-dose intravenous
Description: Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
Study: NCT02297607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tube Feeding
Study: NCT04501809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: compare misoprostol with combined oxytocin and cervical foly catheter
Description: we will compare using misoprostol alone in one group with oxytocin and cervical catheter in the other group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: compare misoprostol with combined oxytocin and cervical foly catheter
Description: we will compare using misoprostol alone in one group with oxytocin and cervical catheter in the other group
Study: NCT03662711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilator Agents
Description: Fluticasone furoate/vilanterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Tiotropium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Indacaterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Umeclidinium/vilanterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilator Agents
Description: Fluticasone propionate/salmeterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilator Agents
Description: Beclometasone dipropionate/formoterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilator Agents
Description: Budesonide formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Glycopyrronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Aclidinium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Umeclidinium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Indacaterol glycopyrronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Salmeterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Tiotropium olodaterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Aclidinium/formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator Agents
Description: Olodaterol
Study: NCT03657797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX 470
Description: NCX 470 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX 470
Description: NCX 470 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX 470
Description: NCX 470 Ophthalmic Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005%
Description: Latanoprost 0.005% Ophthalmic Solution
Study: NCT00663390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic acid (Dermacid)
Description: Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
Study: NCT01163682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The electro-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
Study: NCT01953484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in extracorporeal carbon dioxide removal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in extracorporeal carbon dioxide removal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in extracorporeal carbon dioxide removal
Study: NCT01942382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
Study: NCT00991601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FNAC (fine needle aspiration cytology)
Description: UL guided biopsy
Study: NCT01736280

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Any evaluation or treatment under this protocol will be based on standard practice as related to the subjects's digestive disorder.These include but are not limited to biobehavioral interventions including bowel retraining, biofeedback, and other lifestyle interventions, all of which have been shown to be beneficial in the treatment of this type of chronic functional bowel disorder.
Study: NCT03462667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stoma Boot Camp
Description: Educational session designed to prepare people for living life with a stoma.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients receive normal pre-surgery standard of care.
Study: NCT01578434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium: 75 mg/kg calcium daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D and Calcium
Description: Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
Study: NCT04550962

Intervention type: DRUG
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:solution Route of administration: subcutaneous~Dose regimen:
Study: NCT02124590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Exercise
Description: Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Exercise
Description: Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
Study: NCT02652780

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS010
Description: Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intravitreal Injection
Description: Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
Study: NCT00403091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
Study: NCT00028834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01060384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Cohort -1\^ 10mg daily on Days 1-21 every 28 days~Dose Cohort +1\^\^ 15mg daily on Days 1-21, every 28 days~Dose Cohort +2 20 mg daily on Days 1-21, every 28 days~Dose Cohort #3 25 mg daily on Days 1-21, every 28 days~\^Used only if Dose Cohort +1 requires further reduction~\^\^Starting Dose Cohort in Phase I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: 8 weekly infusions of ofatumumab 1000mg.
Study: NCT00883389

Intervention type: DEVICE
Intervention: Medical Alert Bracelet
Description: Medical Alert Bracelet alerting health care providers to consider the patient's chronic kidney disease condition when planning care. It also provides a link to a website about safe kidney care (safekidneycare.org)
Study: NCT01936961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTLA-4 Antibody
Description: administered intravenously over 90 minutes every 3 weeks for a total of four doses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Study: NCT01600040

Intervention type: RADIATION
Group type: OTHER
Intervention: Proton radiation therapy
Description: 5 days per week (Mon-Fri) for 5-6 weeks
Study: NCT03662711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilator Agents
Description: Formoterol/glycopyrronium bromide/beclometasone dipropionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilator Agents
Description: Fluticasone furoate/umeclidinium bromide/vilanterol
Study: NCT03899545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serratus Plane Block
Description: 0.5 ml /kg Bupivacaine/lidocaine mixture will be injected onto the serratus muscle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Plane Block plus Pectoral I Block
Description: 0.5 ml / kg %0.25 Bupivacaine/ %1 lidocaine mixture will be injected onto the serratus muscle and injected between the pectoralis minor/pectoralis major muscles.2/3 of the total drug will be applied for the serratus plane block and 1/3 of the total drug for the pectoral I block. If the total amount of the drug is less than 30 ml, it will be completed with isotonic saline to 30 ml.
Study: NCT03030482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: touch massage
Description: Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
Study: NCT01125007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two kind toothbrushes
Description: a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two kind toothbrushes
Description: a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
Study: NCT04056091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Back rub stimulation
Description: Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (back rubs). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foot flicks stimulation
Description: Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (foot flicks). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
Study: NCT01064869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pyscho-behavioural
Description: A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~1. A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~2. Motivational interviewing based on stages of change model to encourage change and adherence~3. Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients
Study: NCT04003103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Islatravir 30 mg capsules taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Islatravir 30 mg capsules taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules taken by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken by mouth.
Study: NCT01895829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
Study: NCT01556165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline
Description: 1 mg/day, tablets, once daily, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets, once daily, orally
Study: NCT00397904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Study: NCT02202902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1H magnetic resonance spectroscopy and CMRI
Description: Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1H magnetic resonance spectroscopy and CMRI
Description: Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1H magnetic resonance spectroscopy and CMRI
Description: Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment